

University of Groningen

## Pharmacological approaches to optimize TB treatment

Zuur, Marlies

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2018

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Zuur, M. (2018). *Pharmacological approaches to optimize TB treatment: An individualized approach*. Rijksuniversiteit Groningen.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

# **Pharmacological approaches to optimize TB treatment**

**An individualized approach**

Marlanka A. Zuur

Zuur, M.A.

Pharmacological approaches to optimize TB treatment; an individualized approach

Thesis, University of Groningen, the Netherlands

Publication of this thesis was financially supported by University of Groningen, University Medical Center Groningen, Graduate School of Medical Sciences, KNCV Tuberculosis foundation, Royal Dutch Pharmacists Association (KNMP) and Stichting Beatrixoord Noord-Nederland.



Cover            Zuur, M.A.

Layout           Zuur, M.A. and Zuur, J.J.

Printed by       ProefschriftenPrinten.nl

ISBN: 978-94-034-0998-6

ISBN: 978-94-034-0997-9 (electronic version)

© Copyright 2018 M.A. Zuur, Groningen, The Netherlands

All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, by photocopying, recording or otherwise, without the prior written permission of the author.



rijksuniversiteit  
 groningen

# Pharmacological approaches to optimize TB treatment

An individualized approach

## Proefschrift

ter verkrijging van de graad van doctor aan de  
 Rijksuniversiteit Groningen  
 op gezag van de  
 rector magnificus prof. dr. E. Sterken  
 en volgens besluit van het College voor Promoties

De openbare verdediging zal plaatsvinden op  
 maandag 19 november 2018 om 14:30 uur

door

**Marlies Anke Zuur**

geboren op 15 januari 1993  
 te Smalingerland

## **Promotores**

Dr. J.W.C. Alffenaar

Prof. dr. T.S. van der Werf

Prof. dr. D.J. Touw

## **Beoordelingscommissie**

Prof. dr. J.W. Mouton

Prof. dr. M.P. Grobusch

Prof. dr. H.A.M. Kerstjens

# Contents



Chapter 1: Introduction (page 6)

Chapter 2: Therapeutic drug monitoring of TB drugs: review (page 14)

Chapter 3a: Intermediate Susceptibility Dose-Dependent Breakpoints For High Dose Rifampicin, Isoniazid and Pyrazinamide, Treatment of MDR-TB in Programmes (page 52)

Chapter 3b: Cost-utility Analysis of Treating Tuberculosis Patients with Intermediate Susceptibility dose-dependent with a Higher Rifampicin and Isoniazid Dose in Europe (page 74)

Chapter 4: TDM and FDC; friend or foe? (page 98)

Chapter 5a: Quality Assessment of Dried Blood Spots from Tuberculosis Patients from Four Countries (page 106)

Chapter 5b: Dried blood spots can help decrease the burden on patients dually infected with multidrug-resistant tuberculosis and HIV (page 118)

Chapter 6a: Evaluation of carbapenems for multi/extensive-drug resistant Mycobacterium tuberculosis treatment (page 126)

Chapter 6b: Pharmacokinetic Modeling and Limited Sampling Strategies based on healthy volunteers for Monitoring of Ertapenem in MDR-TB patients (page 156)

Chapter 6c: Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients (page 174)

Chapter 7: General discussion and future perspectives (page 190)

Summary (page 208)

Dankwoord (page 216)

About the author: (page 222)